Leader cells promote immunosuppression to drive ovarian cancer progression in vivo
Amy L. Wilson & Maree Bilandzic et al. · 2024-11-13
Over 75% of patients with ovarian cancer present with late-stage disease, often accompanied by extensive metastasis. The metastatic cascade is driven by a sub-population of transcriptionally plastic cells known as "leader cells" (LCs), which play a critical role in collective invasion yet remain poorly understood. LCs are marked by the expression of keratin-14 (KRT14), which determines their migratory and invasive capacity in ovarian cancer. This study demonstrates that KRT14+ LCs promote tumor progression through immunosuppression and immune privilege in vivo. In the ID8 syngeneic epithelial ovarian cancer mouse model, tumor-specific loss of KRT14+ LCs impairs tumor progression and metastatic spread without affecting cellular proliferation. Immune profiling shows reduced immunosuppressive regulatory T cells (Tregs) and M2 macrophages and improved CD8
Amy L. Wilson, Laura R. Moffitt, Brittany R. Doran, Bashirah Basri, Jennie Do, Thomas W. Jobling, Magdalena Plebanski, Andrew N. Stephens, Maree Bilandzic